The entrance to one of Novo Nordisk’s two manufacturing facilities in Clayton, North Carolina on June 24, 2024. Brian Gordon [email protected] ...

Novo Nordisk has officially begun building a $1.8 billion production facility for diabetes medicines at its Clayton site that will create 700 high-paying jobs, doubling its workforce there. The ...

Novo Nordisk's $1.8B expansion in Clayton is the single largest manufacturing investment ... recently launched a “Go Global NC” program to expand the connections that link North Carolina to the world ...

Executives mingled with North Carolina leaders in the city of Wilson to ceremonially break ground on Johnson & Johnson’s ...

Novo Nordisk announced that its next-generation weight-loss drug CagriSema helped obese or overweight adult patients with type 2 diabetes lose 15.7% of their weight in a recent trial. That figure ...

Shares of Novo Nordisk slipped in Monday morning trading after the company announced results of its latest weight-loss drug trial. Novo's results from its Redefine 2 late-stage trial of ...

The FDA today declared the national deficit of GLP-1 diet drugs at an end. Well, at least for Novo Nordisk's Ozempic and Wegovy. Novo Nordisk sales should be going up, and Hims & Hers Health's ...

Shares of Novo Nordisk fell on Monday, after the Danish pharmaceutical giant said its next-generation weight-loss drug CagriSema helped obese or overweight adult patients with type 2 diabetes drop ...

Novo Nordisk (NVO) stock was down more than 8% Monday morning after the Danish drugmaker shared new data on its next-generation GLP-1 drug, CagriSema. The drug, a mix of cagrilintide and ...